West Pharmaceutical Services (NYSE:WST) Hits New 52-Week High After Earnings Beat

West Pharmaceutical Services, Inc. (NYSE:WST) shares reached a new 52-week high during mid-day trading on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $386.00 and last traded at $362.5410, with a volume of 169878 shares traded. The stock had previously closed at $358.41.

The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. The firm had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.West Pharmaceutical Services’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS.

West Pharmaceutical Services Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th will be paid a $0.22 dividend. The ex-dividend date is Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is presently 11.76%.

Key West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West posted a strong second quarter, with adjusted EPS of $2.37 and revenue of $872.3 million, both above expectations. The company also raised full-year 2026 EPS guidance and gave third-quarter guidance that topped consensus, which supports the longer-term outlook. West Reports Second-Quarter 2026 Results
• Positive Sentiment: Demand remains strong for high-value injectable drug components, including products tied to GLP-1 and biologics markets, which helped drive the beat and the higher outlook. Reuters article on raised forecast
• Neutral Sentiment: Investors may be taking profits after the stock’s sharp earnings-driven surge in the prior session, especially since there was no major new negative company announcement or filing behind today’s weakness. Quiver Quantitative article
• Neutral Sentiment: Recent insider sales from two executives may add a small overhang, but the activity is limited and does not appear to be the main driver of the stock’s move. Insider trading details

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. BNP Paribas Exane started coverage on West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 price target for the company. TD Cowen reaffirmed a “buy” rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, April 27th. Morgan Stanley boosted their target price on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Finally, Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $310.00 to $400.00 in a report on Tuesday, June 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $363.17.

Insider Buying and Selling

In related news, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares in the company, valued at $457,920.41. The trade was a 37.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.60% of the company’s stock.

Institutional Trading of West Pharmaceutical Services

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Wealth Alliance LLC increased its stake in West Pharmaceutical Services by 3.8% during the 1st quarter. Wealth Alliance LLC now owns 945 shares of the medical instruments supplier’s stock worth $237,000 after buying an additional 35 shares during the period. Darwin Wealth Management LLC raised its stake in West Pharmaceutical Services by 10.8% in the fourth quarter. Darwin Wealth Management LLC now owns 410 shares of the medical instruments supplier’s stock valued at $113,000 after buying an additional 40 shares in the last quarter. IFM Investors Pty Ltd raised its stake in West Pharmaceutical Services by 0.3% in the first quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock valued at $3,452,000 after buying an additional 43 shares in the last quarter. Compound Planning Inc. lifted its holdings in West Pharmaceutical Services by 3.6% during the 1st quarter. Compound Planning Inc. now owns 1,224 shares of the medical instruments supplier’s stock worth $307,000 after buying an additional 43 shares during the last quarter. Finally, Aptus Capital Advisors LLC lifted its holdings in West Pharmaceutical Services by 5.5% during the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock worth $249,000 after buying an additional 47 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Trading Down 7.6%

The firm has a market capitalization of $23.22 billion, a price-to-earnings ratio of 42.08, a PEG ratio of 2.77 and a beta of 1.16. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.82. The company has a 50-day moving average price of $337.02 and a 200-day moving average price of $287.43.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.